Congruence Therapeutics Announces Participation at the Citi Biotech Private Access Day and 2025 Bloom Burton & Co. Healthcare Conferences

MONTREAL, April 22, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's disease and AAT-deficient lung and liver disease, announced today its participation in upcoming investor conferences:

    --  Citi Biotech Private Access Day, April 24, 2025 - this event is being
        held in a virtual format during which Company management will
        participate in one-on-one meetings with investors.

    --  Bloom Burton & Co. Healthcare Conference, May 4-6, 2025 - Dr. Clarissa
        Desjardins, Chief Executive Officer of Congruence, will present on
        Monday, May 5, 2025, at 1:30 PM ET. Company management will also
        participate in one-on-one meetings with investors during the event.

About Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir(TM), captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and 1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two recently executed multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases.

For more information, please visit www.congruencetx.com.

Company Contact
Charles Grubsztajn
Chief Operating Officer
cgrubsztajn@congruencetx.com

Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

View original content to download multimedia:https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-at-the-citi-biotech-private-access-day-and-2025-bloom-burton--co-healthcare-conferences-302434838.html

SOURCE Congruence Therapeutics